- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04159402
Dissect Assembly Rules of SPET12 Complex in the Mammalian Sperm
October 3, 2022 updated by: National Cheng-Kung University Hospital
Medical Doctors(Department of Obstetrics and Gynecology)
The sperm of the KO mouse shothe investigatorsd severe defects of all found compartments: acrosome, nucleus, midpiece and tail.
The investigators also found SEPT12 co-localizes and interact with SEPT1, 2, 4, 6, 7, 10, 11, and 14 in sperm.
Interestingly, some of these septins form filaments with SEPT12 in cells.
Based on these findings, it is hypothesized that (1) The core complex of SEPT12 filament consists of SEPT12-7-6-2-2-6-7-12; (2) Septin12 mutations, genetic variants, as the investigatorsll as haploinsufficiency disrupt SEPT12 filament and macro-complex; (3) Other SEPT's (e.g.
SETP4, SEPT14) are also involved in the functionality of SEPT12; and (4) SEPT12 macro-complex is critical for compartment formation during terminal differentiation of male germ cells.
The proposed study is designed to confirm the above hypotheses, to deconstruct mammalian SEPT12 complex, and to elucidate the functional significance of Septin12 mutations.
In the proposed study, the investigators will use different methods, including proteomics, immunofluorescence assay, co- immunoprecipitation, pull-down assay, protein domain mapping, and protein complex fractionation to test the above hypothesis.
The investigators have created a mouse carrying an important Septin12 mutation.
In the proposed study, the investigators plan to knock out Septin14 in the mouse.
SEPT14 interacts with SEPT12 and is also predominantly expressed in sperm.
The mouse models and research tools could be used to explore the role of septins during spermiogenesis, to deconstruct the SEPT12 complex in the mammalian sperm, and to elucidate the functional significance of the Septin 12 mutations.
Our findings may provide novel insight into the pathways human spermatogenesis, and has the potential to lead to development of therapeutic models for male infertility, and design of male contraceptives.
Study Overview
Status
Completed
Conditions
Detailed Description
Redundancy and Interchangeability of Septins Septins 3, 4, 5, 6, 11, and 12 have been knocked out in the mouse model.
Although SEPT4 abundantly expressed in different tissues, Septin4 KO mice only shothe investigatorsd male reproductive failure.
SEPT12 is exclusively expressed in the post-meiotic germ cells, and Septin12+/- KO mice shothe investigatorsd spermatogenetic failure.
In one study, SEPT5 deficiency decreased anxiety-related behavior, increased prepulse inhibition and delayed acquisition of rewarded goal approach, independent of mouse genetic backgrounds.
In another study, Septin3-/- and Septin5-/-mice did not show any overt phenotypes.
Knockout of a ubiquitously expressed septin, Septin6, also did not result in abnormal phenotypes.
SETP11 is ubiquitously expressed, and Sept11 null mutation died in utero.
The findings suggest redundancy and interchangeability of many septin family members.
Among the septin family members, SEPT12 and 14 may deserve special attention for the reproductive biologists because they are mainly expressed in the testis.
Study Type
Observational
Enrollment (Actual)
183
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Sampling Method
Probability Sample
Study Population
The participants were clinically diagnosed by semen analysis and further collected the normal human sperm.
Description
inclusion criteria:
- All participants signed a written informed consent form.
- Semen samples were obtained by masturbation after 3-5 days of sexual abstinence.
exclusion criteria:
.None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Losses of SEPT12, SEPT7, SEPT6, SEPT2 and SEPT4 from the sperm annulus of a SEPT12D197N patient.
Time Frame: 1 day
|
Immunofluorescence staining of normal sperm in a fertile control showed signals for SEPT12 .
SEPT7, SEPT6, SEPT2 and SEPT4 (red) at the annulus.
Also shown are merged fluorescence staining images with the additional staining of the sperm nuclei, as well as merged fluorescence staining images with merged brightfield images (BF merged).
Blue color, DAPI stain; BF, brightfield only.
Scale bar: 10 µm.
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2014
Primary Completion (Actual)
July 1, 2017
Study Completion (Actual)
July 1, 2017
Study Registration Dates
First Submitted
October 28, 2019
First Submitted That Met QC Criteria
November 7, 2019
First Posted (Actual)
November 12, 2019
Study Record Updates
Last Update Posted (Actual)
October 4, 2022
Last Update Submitted That Met QC Criteria
October 3, 2022
Last Verified
November 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- A-ER-102-438
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fertility
-
Next Life SciencesClinico Pty LtdRecruitingFertility | Healthy Male Adults | Fertility, MaleAustralia
-
Charite University, Berlin, GermanyKarl and Veronica Carstens FoundationTerminatedFertility Issues | Fertility Disorders | IVF | Sub Fertility, Female | Sub-fertilityGermany
-
Sandstone DiagnosticsCompletedFertility, Male | Sub-Fertility, MaleUnited States
-
Centre Hospitalier Universitaire, AmiensRecruitingOncology | Live Birth Rate | Fertility Preservation | Assisted Reproductive Technology | Reproductive Health | Cancer Remission | Reproductive Outcomes | Fertility Counseling | Psychological Impact | Fertility Observatory | Patient Follow-up | Female Cancer Survivors | Fertility Preservation TechniquesFrance
-
Fundación Santiago Dexeus FontRecruiting
-
Lady Technologies IncActive, not recruiting
-
Ferring PharmaceuticalsTerminatedFertilitySpain, Belgium, Czechia, Denmark, Norway
-
University of NottinghamCompleted
-
Ava AGUniversity Hospital, Zürich; Empa, Swiss Federal Laboratories for Materials... and other collaboratorsCompleted
-
University of SaskatchewanCanadian Institutes of Health Research (CIHR)Completed